

**INDUCTION OF DRUG  
RESISTANCE AND  
DIFFERENTIATION IN HUMAN  
LEUKAEMIA CELL LINES**

**Denese Marks**

**PhD  
1994**

## **Acknowledgements**

I gratefully acknowledge my supervisors, Dr. Mary Davey for her guidance, most valuable advice and discussions and Dr. Antony Kidman for providing the support which made this project possible.

I also wish to thank Dr. Ross Davey and the staff of the Bill Walsh Cancer Research Laboratory of Royal North Shore Hospital for their guidance and helpful discussions. Also thanks to the Prof. R. Raison, and Stuart Tangye of the Immunobiology Unit, UTS, for their valuable advice and use of the flow cytometer.

Most of all I wish to dedicate this Thesis to Murray.

## ABSTRACT

The ability of low, clinically relevant levels of the chemotherapeutic drugs epirubicin and vinblastine to induce drug resistance was examined in the K562, U937, KG-1a and HEL human leukaemia cell lines. Treatment with epirubicin and vinblastine induced the MDR phenotype and P-glycoprotein expression in K562 and U937 cells. However this treatment had no effect on drug resistance in the P-glycoprotein expressing KG-1a and HEL cells. In the U937 cells, drug resistant cells were not only MDR but were also resistant to other drugs including cisplatin and chlorambucil which are not normally associated with MDR. The drug resistant U937 sublines were also sensitised to doxorubicin, cisplatin and chlorambucil by buthionine sulfoximine (BSO), suggesting that glutathione-related mechanisms also contributed to resistance in these sublines. The U937 sublines also had an increased DNA content and an increased ability to recover from DNA damage, as determined by cell cycle analysis, indicating that the broad cross-resistance exhibited by these cells was due to the co-existence of multiple resistance mechanisms. Drug treatment induced changes in expression of differentiation associated antigens in all four cell lines.

Treatment with inducers of differentiation (TPA, sodium butyrate, granulocyte-macrophage colony-stimulating factor; GM-CSF). Treatment of K562 and K562/E15B cells with TPA induced megakaryocytic differentiation, with increases in drug resistance, and increased P-glycoprotein expression in the K562/E15B subline. TPA induced monocytic differentiation in the U937 cells but not the U937/E15 subline, with increased P-glycoprotein expression and function in the U937/E15 cells but not the U937 cells. Staurosporine, an inhibitor of PKC, inhibited differentiation in these cell lines, but did not inhibit increases in P-glycoprotein expression, suggesting drug resistance was not mediated by PKC.

Sodium butyrate induced erythroid differentiation, and increased P-glycoprotein expression in the K562/E15B cells. However at a higher concentration (15 mM) this was not accompanied by increased drug resistance. Granulocyte monocyte colony stimulating factor (GM-CSF) did not induce differentiation in the K562 cells or K562/E15B subline, although the K562/E15B cells became more drug resistant after treatment with GM-CSF. Treatment with GM-CSF induced differentiation in the U937/E15 subline but did not change drug resistance in either the U937 cells or the U937/E15 subline.

Therefore the P-glycoprotein expressing K562/E15B and U937/E15 sublines were more responsive to inducers of differentiation than the parental cell lines. Induction of differentiation therefore induced increases in P-glycoprotein expression and drug resistance, suggesting that expression of P-glycoprotein or a multidrug resistance phenotype was associated with differentiation.

## Abbreviations

<b>Abbreviation</b>	<b>Full Name</b>
AML	acute myeloid leukaemia
ALL	acute lymphocytic leukaemia
APAAP	alkaline phosphatase anti-alkaline phosphatase
BCIP	5-bromo,4-chloro,3-indolyphosphate
BSO	buthionine sulphoximine
CML	chronic myeloid leukaemia
CLL	chronic lymphocytic leukaemia
COL	colchicine
DMSO	dimethylsulfoxide
DNR	daunorubicin
DOX	doxorubicin
DTT	dithiothreitol
EDTA	ethylene diamine triacetic acid
EPR	epirubicin
GM-CSF	granulocyte-macrophage colony-stimulating factor
GSH	glutathione (reduced)
GST	glutathione-S-Transferase
h	hour
IDA	idarubicin
MDR	multidrug resistance
min	minutes
MTT	3-4,5-dimethylthiazol-2,5 diphenyl tetrazolium bromide
NBT	nitro blue-tetrazolium
PAGE	polyacrylamide gel electrophoresis
PI	propidium iodide
PBS	phosphate buffered saline
PKC	protein kinase C
Rh123	rhodamine 123
SDS	sodium dodecyl sulphate
STP	staurosporine
TBS	tris buffered saline
TEMED	tetramethylethylenediamine
topo II	topoisomerase II

TPA	12-O-tetradecanoylphorbol-13-acetate
VCR	vincristine
VER	verapamil
VLB	vinblastine
VP-16	etoposide

## **PUBLICATIONS**

1. Denese C. Marks, Larissa Belov, Mary W. Davey, Ross A. Davey and Antony D. Kidman. (1992) The MTT cell viability assay for cytotoxicity testing in multidrug resistant human leukemic cells. *Leukemia Research*, **16**;1165-1173.
2. Denese C. Marks, Mary W. Davey, Ross A. Davey and Antony D. Kidman. (1993) Differentiation and multidrug resistance in response to drug treatment in the K562 human leukaemia cell line. *British Journal of Haematology*, **84**;83-89.

## **ABSTRACTS AND PRESENTATIONS**

1. Poster presentation entitled "The establishment of a colorimetric (MTT) assay for cytotoxicity testing" at the Australian Society for Biochemistry and Molecular Biology. Sydney, Australia. September, 1990.
2. Poster presentation entitled "Development and characterisation of drug resistant K562 cell lines" at the American Association for Cancer Research Special Conference: Membrane transport in multidrug resistance, development and disease. Banff, Alberta, Canada. March, 1991.
3. Poster presentation entitled "Is P-glycoprotein clinically relevant" at the Australian Society for Medical Research. Canberra, Australia. December, 1991.
4. Poster presentation entitled "Induction of haematopoietic differentiation and multidrug resistance in human leukaemic cell lines" at the Australian Society for Medical Research conference. Brisbane, Australia. December, 1992.
5. Poster presentation entitled "Induction of haematopoietic differentiation and multidrug resistance in human leukaemic cell lines" at the General Motors Cancer Research Foundation International Symposium "Resistance against anticancer drugs: Molecular mechanisms and clinical opportunities". Toronto, Canada. May, 1993.
6. Oral presentation entitled "Induction of megakaryocytic differentiation and drug resistance in human leukaemic K562 cell lines" at the Royal North Shore Hospital/University of Technology, Sydney Annual Scientific Meeting. Sydney, Australia. November, 1993.

# TABLE OF CONTENTS

Acknowledgements.....	i
Abstract.....	ii
Abbreviations.....	iii
Publications, abstracts and presentations.....	v

## INTRODUCTION

1 Characteristics of P-glycoprotein and Multidrug Resistance.....	1
1.1 Putative Structure of P-glycoprotein.....	1
1.2 Detection of P-glycoprotein.....	2
1.3 The <i>mdr</i> genes.....	4
1.3.1 Regulation of the <i>mdr1</i> gene.....	4
1.3.2 The <i>mdr3</i> gene.....	5
1.3.3 Functional Studies Using <i>mdr1</i> and <i>mdr3</i> Mutants.....	5
1.4 Post-translational Modifications of P-glycoprotein.....	5
1.4.1 Glycosylation of P-glycoprotein.....	5
1.4.2 Phosphorylation of P-glycoprotein: The Role of Protein Kinase C.....	6
1.5 P-glycoprotein Function.....	6
1.5.2 ATPase Activity of P-glycoprotein.....	6
1.5.1 Drug Binding Sites.....	6
1.6 Reversal of MDR.....	7
1.6.1 Verapamil.....	7
1.6.2 Other Agents.....	8
1.6.3 Clinical Trials with Modulators of MDR.....	8
1.7 Physiological Role of P-glycoprotein.....	9
1.7.1 Tissue Distribution of P-glycoprotein.....	10
1.7.2 Physiological Function of P-glycoprotein.....	10
2 P-glycoprotein Expression and Prognosis in Leukaemia.....	11
2.1 P-glycoprotein and Cell Surface Antigens as Prognostic Markers in Leukaemia.....	12
3 Other Mechanisms of Drug Resistance.....	12
3.1 Overexpression of Glutathione and GST.....	13
3.2 Altered Intracellular Transport.....	14
3.3 The Multidrug-Resistance associated Protein, MRP.....	15
3.4 Other Membrane Proteins Associated with Drug Resistance.....	15
3.5 Drug Detoxification Mechanisms.....	15
3.6 Methotrexate Resistance.....	16
4 Outline of Thesis.....	17

## MATERIALS AND METHODS

1 Chemicals.....	19
2 Cell Culture.....	19
2.1 Generation of Drug Resistant K562 Sublines.....	20
2.2 Generation of Drug Resistant U937 and HEL Sublines.....	20
2.3 Generation of Drug Resistant KG-1a Sublines.....	20
3 Cytotoxicity Assays.....	20
3.1 The MTT Assay.....	21
4 Effect of Verapamil.....	21
5 Effect of BSO.....	21
6 Detection of P-glycoprotein.....	21
6.1 Western Blot Analysis.....	21
6.1.1 Isolation of Plasma Membrane Fractions.....	21
6.1.2 Electrophoretic Separation of Plasma Membrane Fractions.....	22
6.1.3 Detection of P-glycoprotein.....	22
6.2 Immunocytochemistry.....	23

6.3	Flow Cytometry	23
7	Determination of P-glycoprotein Function Using Rhodamine 123	24
8	Expression of Cell Surface Antigens	24
9	Treatment with TPA	24
10	Treatment with Sodium Butyrate	25
11	Treatment with GM-CSF	25
12	Cell Cycle Analysis	25

## RESULTS AND DISCUSSION

1	DEVELOPMENT AND CHARACTERISATION OF DRUG RESISTANCE IN K562 CELLS	26
1.1	Introduction	26
1.1.1	Cytotoxic Mechanisms and Pharmacokinetics of Epirubicin and Vinblastine	26
1.1.2	K562 Cells as a Model of Haematopoietic Differentiation	28
1.1.3	Outline	28
1.2	Characterisation of Drug Resistance	28
1.3	P-Glycoprotein Expression	29
1.3.1	Western Blot Analysis	29
1.3.2	Immunocytochemistry	30
1.3.3	Flow Cytometry	30
1.4	Cloning	32
1.5	Reversal of Resistance	32
1.6	Rhodamine 123 Accumulation	32
1.7	Expression of Antigens Associated with Differentiation	33
1.7.1	Expression of CD13	33
1.7.2	Glycophorin A	34
1.7.3	Others Antigens	34
1.8	Cell Morphology	34
1.9	Discussion	34
2	DEVELOPMENT AND CHARACTERISATION OF DRUG RESISTANCE IN U937 CELLS	39
2.1	Introduction	39
2.2	Characterisation of Drug Resistance	39
2.3	P-glycoprotein Expression	40
2.4	Reversal of Resistance	40
2.5	Effect of Buthionine Sulphoximine	42
2.6	Rhodamine 123 Accumulation	43
2.7	Cell Morphology	44
2.8	Effects of VP-16 on Cell Cycle	44
2.9	Expression of Antigens Associated with Differentiation	45
2.10	Discussion	45
3	DEVELOPMENT AND CHARACTERISATION OF DRUG RESISTANCE IN THE KG-1a AND HEL CELLS	51
3.1	Introduction	51
3.2	The KG-1a Sublines	51
3.2.1	Development of Drug Resistance	51
3.2.2	P-glycoprotein Expression and Function	51
3.2.3	Differentiation Markers	53
3.2.4	Cell Morphology of KG-1a sublines	53
3.3	The HEL Sublines	53
3.3.1	Development of Drug Resistance	53
3.3.2	P-glycoprotein Expression and Function	53
3.3.3	Differentiation Antigens	54

3.3.4 Cell morphology of HEL sublines .....	54
3.4 Discussion.....	54
<b>4 INDUCTION OF DIFFERENTIATION IN K562 AND K562/E15B CELLS .....</b>	<b>56</b>
4.1 Introduction .....	56
4.2 Induction with TPA .....	59
4.2.1 The Effect of TPA on Differentiation .....	59
4.2.2 The Effect of TPA on Drug Resistance .....	60
4.2.3 The Effect of TPA on P-glycoprotein Expression.....	60
4.2.4 The Effects of TPA on Rh123 Accumulation .....	61
4.3 Induction with Sodium Butyrate.....	61
4.3.1 The Effect of Sodium Butyrate on Differentiation.....	61
4.3.2 The Effect of Sodium Butyrate on Drug Resistance.....	61
4.3.3 The Effects of Sodium Butyrate on P-glycoprotein Expression .....	62
4.3.4 The Effect of Sodium butyrate on Rh123 Accumulation .....	62
4.4 Induction with GM-CSF.....	63
4.4.1 The Effect of GM-CSF on Differentiation.....	63
4.4.2 The Effect of GM-CSF on Drug Resistance .....	63
4.5 Discussion.....	63
4.5.1 Induction with TPA .....	63
4.5.2 Induction With Sodium Butyrate .....	65
4.5.3 Induction with GM-CSF .....	66
<b>5 INDUCTION OF DIFFERENTIATION IN U937 AND U937/E15 CELLS .....</b>	<b>68</b>
5.1 Introduction .....	68
5.2 Induction with TPA .....	68
5.2.1 The Effect of TPA on Differentiation .....	68
5.2.2 The Effect of TPA on Drug Resistance .....	69
5.2.3 The Effect of TPA on P-glycoprotein Expression.....	69
5.2.4 The Effect of TPA on Rh123 Accumulation .....	69
5.3 Induction with GM-CSF.....	69
5.3.1 The Effect of GM-CSF on Differentiaton .....	69
5.3.2 The Effect of GM-CSF on Drug Resistance .....	70
5.4 Discussion.....	70
5.4.1 Induction with TPA.....	70
5.4.2 Induction with GM-CSF .....	73
<b>CONCLUSIONS.....</b>	<b>74</b>
<b>BIBLIOGRAPHY .....</b>	<b>77</b>